The Quest for Targets Executing MYC-Dependent Cell Transformation

Markus Hartl*

Institute of Biochemistry and Center of Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria

MYC represents a transcription factor with oncogenic potential converting multiple cellular signals into a broad transcriptional response, thereby controlling the expression of numerous protein-coding and non-coding RNAs important for cell proliferation, metabolism, differentiation, and apoptosis. Constitutive activation of MYC leads to neoplastic cell transformation, and deregulated MYC alleles are frequently observed in many human cancer cell types. Multiple approaches have been performed to isolate genes differentially expressed in cells containing aberrantly activated MYC proteins leading to the identification of thousands of putative targets. Functional analyses of genes differentially expressed in MYC-transformed cells had revealed that so far more than 40 upregulated or downregulated MYC targets are actively involved in cell transformation or tumorigenesis. However, further systematic and selective approaches are required for determination of the known or yet unidentified targets responsible for processing the oncogenic MYC program. The search for critical targets in MYC-dependent tumor cells is exacerbated by the fact that during tumor development, cancer cells progressively evolve in a multistep process, thereby acquiring their characteristic features in an additive manner. Functional expression cloning, combinatorial gene expression, and appropriate in vivo tests could represent adequate tools for dissecting the complex scenario of MYC-specified cell transformation. In this context, the central goal is to identify a minimal set of targets that suffices to phenocopy oncogenic MYC. Recently developed genomic editing tools could be employed to confirm the requirement of crucial transformation-associated targets. Knowledge about essential MYC-regulated genes is beneficial to expedite the development of specific inhibitors to interfere with growth and viability of human tumor cells in which MYC is aberrantly activated. Approaches based on the principle of synthetic lethality using MYC-overexpressing cancer cells and chemical or RNAi libraries have been employed to search for novel anticancer drugs, also leading to the identification of several druggable targets. Targeting oncogenic MYC effector genes instead of MYC may lead to compounds with higher specificities and less side effects. This class of drugs could also display a wider pharmaceutical window because physiological functions of MYC, which are important for normal cell growth, proliferation, and differentiation would be less impaired.

Keywords: signal transduction, transcription, genetic, oncogenes, tumor suppressor, carcinogenesis
MYC IS AN ENDPOINT OF MULTIPLE SIGNALING PATHWAYS

Cancer cells are featured by deregulated activation and suppression of proto-oncogenes and tumor suppressor genes, respectively. Tumor cells evolve from a multistep process, resulting in sustained proliferation, inactivation of growth suppressors, immortalization, accelerated angiogenesis, metastasis, and resistance to programed cell death. In normal tissues, growth-promoting signals are carefully controlled leading to cellular homeostasis, whereas in cancer cells, these biological signals are deregulated. Signals are transmitted by growth factors, which bind to cell surface receptors containing intracellular tyrosine kinase domains. From here, the signal branches into multiple and complex signal transduction pathways to regulate cell cycle progression, cell growth, survival, and energy metabolism (1). Key players in these processes are encoded by genes, which are normally required to coordinate proper cell metabolism, proliferation, and differentiation. The functions of many of these genes had been elucidated after their identification as transforming principles in oncogenic retroviruses, which carry mutated versions in their genomes (2).

Some of the most intensively studied oncogenes encode transcription factors that are functionally located at the end of several signaling cascades, thereby integrating multiple cellular signals. Transcription factors regulate gene expression and similar to cytoplasmic key regulators, the deregulation of many transcription factors is associated with human oncogenesis. Transcription factors bind to the DNA control regions of target genes and activate or suppress their expression, which is important for cell proliferation and differentiation. In case of aberrant gene regulator activities caused by mutations, distinct target genes become abnormally activated or deactivated, which can ultimately lead to oncogenic transformation and malignant cell growth. MYC represents a prototypic transcription factor and a nuclear end point of several signaling pathways (3) (Figure 1). Hence, identification and characterization of transformation-relevant target genes acting downstream of MYC is a prerequisite to understand molecular mechanisms of tumor development in which this oncogenic transcription factor is involved.

ORIGIN OF MYC AND BIOLOGICAL FUNCTIONS

MYC has been originally identified as the transforming determinant (v-myc) of avian acute leukemia virus MC29 in chicken (myelocytomatosis virus 29) (6). MYC was also isolated from the avian leukemia- and carcinoma-inducing MH2 virus, which carries in addition the v-mil (RAF) allele encoding a serine/threonine protein kinase (7). The presence of two oncogenes significantly increases the oncogenicity of MH2, which is due to cooperative effects between the v-Myc and v-Mil (RAF) proteins (8, 9).

The v-myc allele is derived from the cellular c-myc proto-oncogene by retroviral transduction (10, 11). C-MYC encodes the c-MYC protein, a transcription factor with oncogenic potential representing the central hub of a network controlling the expression of at least 15% of all human genes, and regulating fundamental cellular processes, such as growth, proliferation, differentiation, metabolism, pluripotency, and apoptosis (3, 12). Transcriptional deregulation of human c-MYC caused by chromosomal translocation was first observed in Burkitt’s lymphoma (13).

Besides retroviral insertion or transduction of human c-MYC leading to the development of lymphomas and carcinomas,
amplification of MYC alleles has been observed in colon carcinoma, neuroblastoma, and lung cancer leading to the discovery of the N-MYC and L-MYC paralogs (11). Constitutive activation of MYC is required for oncogenesis and occurs in many human tumor cell lines indicating that deregulated expression of this oncoprotein may contribute to cancer formation. In fact, besides the K-RAS and B-RAF oncoproteins, c-MYC represents a major driver in human tumorigenesis (11, 14). Ectopic expression of c-MYC suffices to induce metastasis in a murine non-small-cell lung cancer (NSCLC) model featuring the most lethal human cancer due to its high metastasis rate. Likewise, in prostate and pancreatic cancer, c-MYC is upregulated upon constitutive stimulation of the RAS and WNT pathways (15–19) (Figure 1). Immortalization and transformation of human epithelial cells occur after overexpressing c-MYC and simultaneously inactivating cyclin-dependent kinase inhibitor 2A (CDKN2A), leading to specific gene expression changes (20, 21). Today, it is known that deregulation of MYC genes is a frequent event in animal and human tumorigenesis taking place in more than 50% of all human cancers (3, 22). MYC proteins therefore belong to those

| Gene    | Activated (+) / suppressed (−) | Protein product | Function | Transformation association | Reference |
|---------|-------------------------------|-----------------|----------|---------------------------|-----------|
| AP4     | +                             | AP4             | Gene regulator | Required for MYC-induced cell cycle progression | (51) |
| BMP7    | +                             | BMP7            | Bone morphogenetic protein | Silencing blocks medulloblastoma cell proliferation | (52) |
| CCNB1   | +                             | Cyclin B1       | CKD regulatory subunit | Induces tetraploidy upon overexpression | (53) |
| CCND2   | +                             | Cyclin D2       | CKD regulatory subunit | Absence inhibits MYC-induced colony formation | (54) |
| CCNE1   | +                             | Cyclin E1       | CKD regulatory subunit | Associated with neuroblastoma progression | (55) |
| CDC25A  | +                             | CDC25           | Cell cycle phosphatase | Induction of apoptosis in growth factor-depleted cells | (56) |
| CDK4    | +                             | CDK4            | Cyclin-dependent kinase | Absence inhibits MYC-induced tumor development | (57) |
| CDT1    | +                             | CDT1            | Chromatin licensing factor | Colony formation in fibroblasts | (58) |
| E2F1    | +                             | E2F1            | Cell cycle regulator | Inhibition of MYC-induced apoptosis | (59) |
| GATA-4  | +                             | GATA-4          | Gene regulator | Knock-down inhibits colony formation | (60) |
| HMG-I/Y | +                             | HMG-I/Y         | Chromatin-binding protein | Tumor generation in nude mice | (61) |
| HSP90A  | +                             | HSP90           | Heat shock protein | Contributes to MYC-induced transformation | (62) |
| JAG2    | +                             | Jagged2         | Notch receptor ligand | Ectopic expression increases tumorigenesis | (63) |
| JPO1    | +                             | JPO1/CDCA7      | Nuclear protein | Ectopic expression increases lymphoid malignancy | (64) |
| LDH-A   | +                             | Lactate dehydrogenase | Enzyme in anaerobic glycolysis | Anchorage-independent growth in rat fibroblasts | (65) |
| MCL1    | +                             | Mcl-1           | Myeloid cell leukemia protein | Abrogation of MYC-driven lymphoma development | (66) |
| MMTN    | +                             | Mmmtin          | Mitochondrial protein | Knock-down leads to tumor cell growth arrest | (67) |
| MTA1    | +                             | MTA1            | NJRD complex component | Knock-down inhibits MYC-induced colony formation | (68) |
| MT-MC1  | +                             | MT-MC1          | Nuclear protein | Tumorigenic activity | (69) |
| NPM     | +                             | Nucleophosmin   | Nuclear protein | Enhances MYC/RAS cotransformation in MEF | (70) |
| ODC     | +                             | Ornithine decarboxylase | Enzyme for polyamine synthesis | Knock-out prevents MYC-induced lymphomagenesis | (71) |
| OPN     | +                             | Osteopontin     | Extracellular signaling protein | Colony formation in primary fibroblasts | (72) |
| PIN1    | +                             | PIN1            | Peptidyl-prolyl isomerase | Genetic ablation reduces MYC-induced lymphomagenesis | (73) |
| PRTA    | +                             | Prothymosin-α   | Chromatin remodeling factor | Induction of anchorage-independent growth | (74) |
| PRDX3   | +                             | Peroxidoxin     | Mitochondrial protein | Colony formation in soft agar | (75) |
| PRMT5   | +                             | Arg methyl transferase | Key enzyme in snRNP assembly | Knock-out in lymphoma cells reduces tumorigenesis | (76) |
| RCL     | +                             | RCL             | Nuclear protein | Colony formation in rat fibroblasts | (77) |
| TFRC1   | +                             | TFRC1           | Transferrin receptor 1 | Enhancement of MYC-mediated tumor formation | (78) |
| Tmp     | +                             | Tmp             | Colony-associated | Colony formation in nude mice | (79) |
| WS5     | +                             | WS5/Pmel17      | Transmembrane glycoprotein | Colony formation in primary avian fibroblasts | (80) |
| p32     | +                             | C1QBP           | Complement component | Inhibition of tumor cell growth upon knock-down | (81) |
| Inc H19 | +                             | n.a.            | Long non-coding RNA | Knock-down decreases cancer cell clonogenicity | (82) |
| BASP1   | −                             | Brain acid-soluble protein | Signaling protein | Inhibition of focus and colony formation | (83) |
| FER-H   | −                             | Ferritin H      | Iron storage protein | Downregulation required for oncogenesis | (84) |
| NDRG1   | −                             | N-myc downregulated gene | Hydrolase | Metastasis suppressor | (85) |
| PRDM11  | −                             | PR-domain protein | Transcriptional regulator | Knock accelerates MYC-induced lymphomagenesis | (86) |
| Onzin   | −                             | Onzin           | Cysteine-rich protein | Oncogenesis upon overexpression | (87) |
| THBS1   | −                             | Thrombospondin  | Antiangiogenic factor | Overexpression reduces tumorigenesis in xenografts | (88) |
| TXNIP   | −                             | Thioredoxin-interacting protein | Negative regulator of glycolysis | Expression reduces cell proliferation | (89) |
| MycL04-6| −                             | n.a.            | Myc-repressed lncRNAs | Prohibits MYC-enhanced cell proliferation | (90) |

**Table 1** Activated and suppressed MYC target genes associated with cell transformation.

**n.a., not applicable.**

**a** Disproportional behaviour.
crucial master switches in most human cancers, from which many of them are associated with a poor clinical outcome (12, 23).

**PRINCIPAL BIOCHEMICAL FUNCTIONS OF MYC**

MYC is a bHLHZip protein encompassing protein dimerization domains (helix–loop–helix, leucine zipper) and a DNA contact surface (basic region) that forms heterodimers with the MAX protein and binds typically to specific DNA sequence elements termed E-boxes (5′-CACGTG-3′) (10, 11). MYC and MAX homologs with conserved basic functions were found in primitive metazoans (24, 25) and premetazoans (26), suggesting that principal functions of the MYC master regulator arose very early in the evolution of multicellular animals.

MYC is regulated at transcriptional and translational levels and stabilized by post-translational modifications, such as RAS-dependent phosphorylation (27). In fact, it has been shown that RAS/ERK and PI3K/AKT signaling cascade significantly increase the half-life of MYC, which is normally subject to rapid ubiquitin-mediated protein degradation (28, 29) (Figure 1). Although MYC is also involved in DNA replication and cell cycle checkpoint processes (30), its major function is transcriptional regulation (11, 12). MYC binds to multiple coactivators representing components of histone acetyltransferase complexes, to ubiquitin ligases, or to other transcription factors, thereby inducing transcriptional activation or repression (10, 11).

**AMPLIFICATION OF GENE EXPRESSION BY MYC**

Previous global analyses, using techniques such as serial analysis of gene expression, DNA microarrays, chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-Seq), promoter scanning, or proteomics, have led to the identification of thousands of genes controlled by the MYC/MAX network, which are involved in fundamental cellular processes, including growth, proliferation, metabolism, differentiation, and apoptosis (31–37). Many of the MYC-activated genes are broadly related to processes of nucleotide synthesis, cell growth, and metabolism, including protein synthesis, ribosomal biogenesis, glycolysis, mitochondrial function, and cell cycle progression (11, 12, 38). In addition, several cell cycle-related genes whose protein products initiate DNA replication are transcriptional MYC targets, which could explain why deregulated DNA synthesis, chromosomal abnormalities, and genomic instability frequently occur in human tumor cells containing activated MYC (39).

Deregulated MYC target genes have been identified in numerous human tumors (11, 40), but so far it has been difficult to ascribe the oncogenic properties of MYC to a defined set of target genes. In fact, results from recent studies indicate that MYC acts as a general amplifier of gene expression (41–43). According to this theory, the promoters of all actively transcribed genes are occupied and activated by c-MYC in tumor cells expressing high levels of this transcription factor, leading to non-linear amplification of existing transcriptional activities (41, 42, 44–46). The observed differential expression of multiple genes in cells containing aberrantly activated MYC is therefore due to individually enhanced gene expression occurring at varying levels. The amplifier model also explains how ectopic c-MYC increases the efficiencies of other transcription factor programs (46), e.g., during generation of pluripotent stem cells from fibroblasts. This re-programing of cells is achieved by overexpressing the transcription factors OCT4, SOX2, and KLF4 (47). On the other hand, gene repression in cells transformed by MYC is caused by MYC interaction with specific transcription factors or indirectly by increasing the expression of repressive transcriptional and chromatin components.

**MYC TARGETS WITH ONCOGENIC OR TRANSFORMATION-SUPPRESSIVE ACTIVITIES**

The conversion of a normal into a tumorigenic cell could be caused by the products of multiple transformation-associated MYC target genes, from which more than 40 have been identified so far (Table 1). Some of these genes exhibit transforming activity upon ectopic expression, suggesting that they contribute to MYC-induced oncogenesis. Furthermore, there is evidence that MYC enhances the effects of other oncogenic gene regulators, such as E2F (48) or AP-1 (9) (Figure 1). In addition to the implication of MYC/MAX heterodimers in transcriptional activation, MYC has been also associated with transcriptional repression, thereby in many cases not binding directly to E-boxes but instead involving other transcription factors such as MIZ-1 or SP1 (3, 12, 46, 49, 50). Most of the genes repressed by MYC are involved in cell cycle arrest, cell adhesion, and cell-to-cell communication (11).

Besides regulating the expression of protein-encoding genes, MYC also controls the expression of distinct long non-coding ribonucleic acids (lncRNA) (78, 85–87) and of multiple small non-coding regulatory microRNAs (miRNA) (3, 88–91). Some of the miRNAs have oncogenic properties such as the miR-17–92 cluster (oncomir-1) or have tumor suppressor functions (16, 85, 88, 92) (Table 1). miRNAs inhibit protein translation or lead to degradation of their target messenger RNAs (mRNA) and have been implicated in cancer by inactivating distinct mRNAs encoding oncogenes or tumor suppressors (93).

**APPROACHES TO IDENTIFY CRITICAL TARGETS EXECUTING MYC-INDUCED CELL TRANSFORMATION**

Transformation-associated targets of MYC either display intrinsic transforming activities or inhibit oncogenesis depending whether they are activated or repressed (Table 1). Assuming that MYC transformation is mainly based on transcriptional deregulation, only the combined effects of multiple activated or suppressed targets may suffice to induce a “MYC-like”
transformed phenotype. However, just systematically analyzing known transformation-relevant MYC targets is not constructive because the list in Table 1 is not exhaustive, and even more important, many of these targets have been isolated from different cellular systems under in vitro cell culture conditions. This may not reflect the real situation in vivo in which oxygen, nutrients, or growth factors are limited. Furthermore, the hypothesis in earlier reductionists’ approaches assuming that a tumor consists of a homogenous collection of cancer cells and its biology is accessible by elucidating all cell autonomous properties and is not valid any more. In human carcinogenesis, diverse cell types from cancer stem cells give rise to intra-tumor heterogeneity, thus further increasing the genetic complexity and representing a major cause of cancer recurrence (1, 94, 95). Cancer cells progressively evolve from normal cells in a multistep process, thereby acquiring distinct characteristic features in an additive manner. Thus, a succession of clonal expansions occurs also involving epigenetic mechanisms such as methylation or histone modification. In particular, the transition to invasion and metastasis encompasses several discrete steps. With regard to this complex scenario, certain in vitro environmental perturbations have to be reconsidered and better adapted to the in vivo situation, for instance, by using isogenic cell lines, which differ only in single allelic mutations (95, 96). More unbiased approaches based on oncogenic functions are required to identify a putative magic target gene set which suffices to phenocopy MYC transformation, supposed that such Holy Grail exists at all. The following approaches are suggested to dissect the complexity of the oncogenic MYC transcriptional program:

**Functional Expression Cloning**

Isolation of novel coding and non-coding MYC targets with strong oncogenic activities could be done by cDNA expression cloning using MYC-dependent tumor cells as a source for RNA isolation. The application of retroviral cDNA expression libraries has already successfully led to the isolation of transforming genes from human tumor cells (97–100). Thereby, the selection for distinct genes is based exclusively on function, in this case the capacity to transform cells. Appropriate gene-transfer tools are retroviral vectors, allowing the efficient introduction of complex cDNA libraries (99, 101) and appropriate screening procedures.

**Combinatorial Gene Expression**

Due to the pleiotropic MYC effect leading to the development of multiple different tumor forms, one could postulate that simultaneous perturbation of multiple targets suffices to convert a normal cell into a cancer cell displaying a MYC-transformed phenotype. Due to the capacity of MYC to enhance existing transcriptional programs (see above), the identification of transcription factors, which are involved in executing the oncogenic MYC program, should be straightforward. Critical MYC targets can then be overexpressed and inactivated depending on whether they are activated and suppressed in MYC-transformed cells, respectively. To simultaneously overexpress multiple genes or interfering RNAs in single cells, several established techniques exist. They are based on different principles such as co-transfection of multiple plasmids, usage of bicistronic vectors containing an internal ribosomal-binding site, infection with retroviruses containing different envelope subtypes, or self-processing peptides (47, 102).

**Analysis of Targets by Permanent Gene Inactivation**

The functionality of critical target genes can be tested by genomic inactivation and the usage of appropriate in vivo tumor model systems. To analyze if expression of a distinct target is required for maintenance of cell transformation, its inactivation should be performed in MYC-dependent tumor cells. Otherwise, to test if a target is required for the initiation of MYC-induced cell transformation, the relevant gene has to be disrupted in normal cells prior to MYC transduction. An appropriate tool for genomic inactivation is the recently developed clustered regularly interspaced short palindromic repeats (CRISPR) system (103, 104). Precise genome editing is achieved by creating specific double-stranded breaks, which allow the generation of homozygous knock-out or knock-in genotypes. Specific MYC target gene inactivation could lead to inhibition of the tumorigenic phenotype, cell cycle arrest, or apoptosis. Suitable in vivo techniques to quantify gene inactivation effects on tumor growth and angiogenesis are, e.g., the generation of mouse xenoplants, and the chicken chorioallantoic membrane assay. Inhibition of tumorigenesis caused by inactivation of MYC distinct targets would indicate essential functions of the tested genes.

**MYC TARGETS AS TEMPLATES FOR INHIBITOR DESIGN**

Because of its pivotal role in cancer, MYC has become an obvious target in the treatment of human cancer cells. Several approaches to interfere with MYC gene transcription, MYC protein function, or with the functions of distinct targets have been pursued to inhibit MYC-dependent pathogenesis.

Intracellular signal transduction pathways regulating MYC expression and protein stability have been targeted by using chemical inhibitors, which are in the trial phase or already applied in the clinic. Thereby, key proteins of the two main signaling cascades responsible for cell survival, differentiation, proliferation, metabolism, and motility were inhibited: the RAS–extracellular signal-regulated kinase (ERK) and the phosphatidylinositol 3-kinase (PI3K) pathways (4, 105, 106) (Figure 1).

Direct inhibition of MYC functions has been achieved by using different strategies. c-MYC transcription has been targeted by inhibiting the chromatin acetyl-lysine recognition domain (bromodomain) of a MYC-specific coactivator. This led to suppression of c-MYC transcription followed by genome-wide downregulation of MYC-dependent target genes (107). C-MYC transcription has been blocked by the miRNA miR-494 leading to inhibition of proliferation, invasion, and chemoresistance in pancreatic cancer (108). Furthermore, a dominant negative mutant of the MYC dimerization domain termed Omomyc is effective against glioma thereby inhibiting cell proliferation and
increasing apoptosis (109). Perturbation of MYC/MAX interaction by synthetic α-helix mimetics or by the homeobox protein Hhex led to impaired DNA binding suppressed transcriptional activation and inhibition of cell growth and tumorigenesis (110, 111). Efficient interference with MYC functions has been also achieved by using novel pyridine inhibitors leading to specific inhibition of MYC/MAX dimerization, transcriptional regulation, and oncogenesis (112, 113). These novel compounds reveal a unique inhibitory potential even at nanomolar concentrations combined with the specific inhibition of MYC-driven tumor growth in vivo (112).

However, under normal physiological conditions MYC is required for many cell physiological processes and for homeostasis. A complete block of the MYC protein by binding to efficient inhibitors may result into undesired side effects or into drug resistance after prolonged application. Approaches based on the principle of synthetic lethality using MYC-overexpressing cancer cells have lead to the identification of targets, which may be susceptible towards appropriate drugs. Synthetic lethality is defined by cell death induced by mutation or inhibition of two different genes, whereas the dysfunction of one gene has no effect on cell viability. This principle can be exploited to screen for anticancer drugs by mimicking the effect of the second genetic mutation using chemical or inhibiting-RNA libraries (114). For instance, pharmacological inhibition of the eukaryotic translation factor eIF4F is synthetic lethal in an Eμ- MYC lymphoma model (115). Likewise, selective death of MYC-dependent human breast cancer cells was achieved by siRNA-mediated inhibition of cyclin-dependent kinase 1 (CDK1) (116). Another example is the identification of a DNA repair protein kinase (PRKDC) as a synthetic lethal target in MYC-overexpressing lung cancer cells, which was identified in RNAi library screen (117). Therefore, attacking oncogenic MYC effectors may increase the specificity of MYC-dependent tumor treatment and enlarge the arsenal of available drugs.

**AUTHOR CONTRIBUTIONS**

The author confirms being the sole contributor of this work and approved it for publication.

**FUNDING**

The work was supported by the Austrian Science Foundation grant P18148.

**REFERENCES**

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646–74. doi:10.1016/j.cell.2011.02.013

2. Vogt PK. Retroviral oncosgenes: a historical primer. Nat Rev Cancer (2012) 12:639–48. doi:10.1038/nrc3320

3. Dang CV. MYC on the path to cancer. Cell (2012) 149:22–35. doi:10.1016/j.cell.2012.03.003

4. Mendoza MC, Er EE, Bennis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 36:320–8. doi:10.1016/j.tibs.2011.03.006

5. Hartl M, Bister K. Oncogenes. 2nd ed. In: Maloy S, Hughes K, editors. Brenner's Encyclopedia of Genetics. (Vol. 5). San Diego: Academic Press (2013), p. 164–6.

6. Bister K, Hayman MJ, Vogt PK. Defectiveness of avian myelocytomatosis virus MC29: isolation of long-term nonproducer cultures and analysis of virus-specific polypeptide synthesis. Virology (1977) 82:431–48. doi:10.1016/0042-6822(77)90017-4

7. Jansen HW, Lurz R, Bister K, Bonner TI, Mark GE, Rapp UR. Homologous cell-derived oncornes in avian carcinoma virus MH2 and murine sarcoma virus 3611. Nature (1984) 307:281–4. doi:10.1038/307281a0

8. Bister K, Jansen HW. Oncogenes in retroviruses and cells: biochemistry and molecular genetics. Adv Cancer Res (1986) 47:99–188. doi:10.1016/S0065-230X(08)60099-2

9. Hartl M, Karagannidis AL, Bister K. Cooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasis. Oncogene (2006) 25:4043–55. doi:10.1038/sj.onc.1209441

10. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol (2005) 6:635–45. doi:10.1038/nrm1703

11. Conacci-Sorrell M, McFerrin L, Eisenman RN. An overview of MYC and its interactor. Cold Spring Harb Perspect Med (2014) 4:a014357. doi:10.1101/cshperspect.a014357

12. Eilers M, Eisenman RN. Myc’s broad reach. Nature (2008) 22:2755–66. doi:10.1038/nature07140

13. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 79:7824–7. doi:10.1073/pnas.79.24.7824

14. Holdener M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 14:455–67. doi:10.1038/nrc3760

15. Maramon F, Caccarelli G, Zani BM. Down-regulation of c-MYC following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer (2006) 5:31. doi:10.1186/1476-4598-5-31

16. Coppola V, De Maria R, Bonci D. microRNAs and prostate cancer. Endocr Relat Cancer (2010) 17:F1–17. doi:10.1677/ERC-09-0172

17. Wang J, Kobayashi T, Flo’c’h N, Kinkade CW, Aytes A, Dankort D, et al. B-Raf activation cooperates with PTEN loss to drive c-MYC expression in advanced prostate cancer. Cancer Res (2012) 72:4765–76. doi:10.1158/0008-5472.CAN-12-0820

18. Castro IC, Breiling A, Luerkenhaus K, Ceteci F, Haussmann S, Kress S, et al. MYC-induced epigenetic activation of GATA4 in lung adenocarcinoma. Mol Cancer (2013) 11:161–72. doi:10.1186/1541-7786.MCR-12-0414-T

19. Hessmann E, Schneider G, Ellenrieder V, Sivieke JT. MYC in pancreatic cancer: novel insights and their translation into therapeutic strategies. Oncogene (2016) 35:1609–18. doi:10.1038/onc.2015.216

20. Garbe JC, Vrba L, Sputova K, Fuchs L, Novak P, Brothman AR, et al. Immortalization of normal human mammary epithelial cells in two steps by direct targeting of senescence barriers does not require gross genomic alterations. Cell Cycle (2014) 13:3423–35. doi:10.4161/cc.2014.95456

21. Vrba L, Garbe JC, Stampfer MR, Futscher BW. A lincRNA connected to cell mortality and epigenetically-silenced in most common human cancers. Epigenetics (2015) 10:1074–83. doi:10.1080/15592294.2015.1106673

22. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene (1999) 18:3004–16. doi:10.1038/sj.onc.1202746

23. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature (2010) 463:899–905. doi:10.1038/nature08822

24. Hartl M, Mitterstiller AM, Valovka T, Breuker K, Hobmayer B, Bister K. Stem cell-specific activation of an ancestral myc protooncogene with conserved basic functions in the early metazoan Hydra. Proc Natl Acad Sci U S A (2010) 107:4051–6. doi:10.1073/pnas.091060107

25. Hartl M, Glasauer S, Valovka T, Breuker K, Hobmayer B, Bister K. Hydra myc2, a unique pre-bilaterian member of the myc gene family, is activated in cell
proliferation and gametogenesis. Biol Open (2014) 3:397–407. doi:10.1242/bio.20147005

26. Youl, SL, Diolati D, Conacci-Sorrenti M, Ruiz-Trillo I, Eisenman RN, King N. Premetazoan ancestry of the Myc-Max network. Mol Biol Evol (2011) 28:2961–71. doi:10.1093/molbev/msr132

27. Jackstadt R, Mensen A, Hermeking H. Genome-wide analysis of c-MYC-regulated miRNAs and miRNAs, and c-MYC DNA binding by next-generation sequencing. Methods Mol Biol (2013) 1012:145–85. doi:10.1007/978-1-62703-429-6_11

28. Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell (1999) 3:169–79. doi:10.1016/S1097-7857(00)80308-1

29. Tsai WB, Alba I, Long Y, Lin HK, Feun L, Savaraj N, et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res (2012) 72:2622–33. doi:10.1158/0008-5472.CAN-11-3605

30. Herold S, Herbert K, Eilers M. Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer (2009) 9:441–4. doi:10.1038/nrc2640

31. Mensen A, Hermeking H. Characterization of the c-Myc-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A (2002) 99:6274–9. doi:10.1073/pnas.082005599

32. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-MYC in Burkitt’s lymphoma cells. Proc Natl Acad Sci U S A (2003) 100:8164–9. doi:10.1073/pnas.1332764100

33. Marinkovic D, Marinkovic T, Kokić E, Burth T, Moller P, Wirth T. Identification of novel Myc target genes with a potential role in lymphomagenesis. Nucleic Acids Res (2004) 32:5368–78. doi:10.1093/nar/gkh777

34. Kim J, Lee JH, Iyer VR. Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One (2008) 3:e1798. doi:10.1371/journal.pone.0001798

35. Seitz V, Butzhammer P, Hirsch B, Hecht J, Güttgemann I, Eilers A, et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma cells. Cell Cycle (2011) 10:2184–96. doi:10.4161/cc.10.13.16249

36. Perna D, Fagà G, Verrecchia A, Gorski MM, Barozzi I, Narang V, et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene (2012) 31:1695–709. doi:10.1038/onc.2011.359

37. Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, metabolism, and cancer. Cancer Discov (2015) 5:1024–39. doi:10.1158/2159-8290.CD-14-0507

38. Dominguez-Sola D, Yng Ch, Grandori C, Ruggiero L, Chen B, Li M, et al. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. PLoS One (2011) 6:e26057. doi:10.1371/journal.pcelrep.2016.02.039

39. Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol (2004) 24:7538–47. doi:10.1128/MCB.24.17.7538-7547.2004

40. Valovka T, Schönfeld M, Rafeiffer P, Breuker K, Dunzendorfer-Matt T, Hartl M, et al. Transcriptional control of DNA replication licensing by Myc. Sci Rep (2013) 3:3444. doi:10.1038/srep03444

41. Wood LJ, Mukherjee J, Dolde CE, Xu Y, Maher JF, Bunton TE, et al. HMG-1/Y, a new c-MYC target gene and potential oncogene. Mol Cell Biol (2000) 20:5490–502. doi:10.1128/MCB.20.15.5490-5502.2000

42. Teng SC, Chen YY, Su YN, Chou PC, Chiang YC, Tseng SF, et al. Direct activation of HSPA90A transcription by c-MYC contributes to c-MYC-induced transformation. J Biol Chem (2004) 279:14646–55. doi:10.1074/jbc.M308842200

43. Yustein JT, Liu YC, Gao P, Jie C, Le A, Vuica-Ross M, et al. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis. J Cell Sci (2010) 123:3534–9. doi:10.1242/jcs.091330107

44. Osthus RC, Karim B, Prescott JE, Smith BD, McDevitt M, Huo DL, et al. The Myc target gene JPO1/CDC47 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer Res (2005) 65:5620–7. doi:10.1158/0008-5472.CAN-05-0536

45. Lewis BC, Prescott JE, Campbell SE, Shim H, Orlowski RZ, Dang CV. Tumor induction by the c-MYC target genes cdl and lactate dehydrogenase A. Cancer Res (2000) 60:6178–83.

46. Grabow S, Delbridge AR, Aubrey BJ, Vandenberg CJ, Strasser A. Loss of a single McI-I allele inhibits MYC-driven lymphomagenesis by sensitizing pro-B cells to apoptosis. Cell Rep (2016) 14:2337–47. doi:10.1016/j.celrep.2016.02.039

47. Tsuone K, Teye K, Arima N, Soejima M, Otera H, Ohashi K, et al. A novel Myc target gene, mimitin, that is involved in cell proliferation of esophageal squamous cell carcinoma. J Biol Chem (2005) 280:19977–85. doi:10.1074/jbc.M301231200

48. Zhang XY, DeSalle LM, Patel JH, Capobianco AJ, Yu D, Thomas-Tikhonenko T, et al. Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A (2005) 102:19368–73. doi:10.1073/pnas.0502330102

49. Baginski KR, Cohen DE, Corcoran DL, Benos PV, Prochownik EV. Derepression of common genes by c-MYC and its direct target, MTC1. Proc Natl Acad Sci U S A (2005) 102:18968–73. doi:10.1073/pnas.0507920102
Kim T, Cui R, Jeon YJ, Lee JH, Sim H, et al. Long-range interaction between MYC enhancer and oncogenic long noncoding RNA CARLo-S. Proc Natl Acad Sci U S A (2014) 111:4173–8. doi:10.1073/pnas.140035011

Hart JR, Roberts TC, Weinberg MS, Morris KV, Vogt PK. MYC regulates the non-coding transcriptome. Oncotarget (2014) 5:12543–54. doi:10.18632/oncotarget.3033

Frenzel A, Lovin J, Henriksen MA. Targeting MYC-regulated miRNAs to combat cancer. Genes Cancer (2010) 1:660–7. doi:10.1177/194769101037748

Bui TV, Mendell JT. MYC: maestro of microRNAs. Genes Cancer (2010) 1:568–75. doi:10.1177/1947691010377491

Song R, Sponder N, He L. Methods to quantify microRNAs in the Myc gene network for posttranscriptional gene repression. Methods Mol Biol (2013) 1012:135–44. doi:10.1007/978-1-62703-429-6_10

Tao J, Zhao X, Tao J. c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies. Cell Cycle (2014) 13:191–8. doi:10.4161/cc.27466

Fontana L, Fiori ME, Albini S, Cifaldi L, Givonuzzi S, Forloni M, et al. Antagonism-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One (2008) 3:e2223. doi:10.1371/journal.pone.0002236

Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 10:704–14. doi:10.1038/nrg2634

Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapies. Br J Cancer (2013) 108:479–85. doi:10.1038/bjc.2012.581

Vermeersch KA, Wang L, McDonald JF, Styczynski MP. Distinct metabolic responses of an ovarian cancer stem cell line. BMC Syst Biol (2014) 8:134. doi:10.1186/s12918-014-0134-9

Hart JR, Zhang Y, Liao L, Ueno T, Lu D, Jonkers M, et al. The butterfly effect in cancer: a single base mutation can remodel the cell. Proc Natl Acad Sci U S A (2014) 111:1136–114. doi:10.1073/pnas.142011122

Foster KW, Ren S, Louro ID, Lobo-Ruppert SM, McKay-Bell P, Grizzle W, et al. Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLK1. Cell Growth Diff (2015) 10:423–43.

Felts KA, Chen K, Zaharee K, Sundar L, Limjoco J, Miller A, et al. Functional cloning using pFB retroviral cDNA expression libraries. Mol Biotechnol (2002) 22:25–32. doi:10.1385/MB:22:1:025

Soda M, Choi YL, Enomoto M, Takada S, Yashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448:561–6. doi:10.1038/nature05945

Choi YL, Soda M, Ueno T, Hamada T, Haruta H, Yamoto A, et al. Oncogenic MAP2K1 mutations in human epithelial tumors. Carcigenesis (2012) 33:956–61. doi:10.1039/carin/bgs099

Loftus SK, Larson DM, Watkins-Chow D, Church DM, Pavan WJ. Generation of RCAS vectors useful for functional genomic analyses. DNA Res (2001) 8:216–21. doi:10.1093/dnares/8.5.221

Gao SY, Jack MM, O'Neill C. Towards optimising the production of and expression from polycistronic vectors in embryonic stem cells. PLoS One (2012) 7:e48668. doi:10.1371/journal.pone.0048668

Charpentier E, Marraffini LA. Harnessing CRISPR-Cas9 immunity for genetic engineering. Curr Opin Microbiol (2014) 19C:114–9. doi:10.1016/j.mib.2014.07.001

Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering. Science (2012) 339:1691–6. doi:10.1126/science.1237270
109. Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, et al. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. *Nat Commun* (2014) 5:4632. doi:10.1038/ncomms5632

110. Jung KY, Wang H, Teriete P, Yap JL, Chen L, Lanning ME, et al. Perturbation of the c-MYC-Max protein-protein interaction via synthetic α-helix mimetics. *J Med Chem* (2015) 58:3002–24. doi:10.1021/jm501440q

111. Marfil V, Blazquez M, Serrano F, Castell JV, Bort R. Growth-promoting and tumourigenic activity of c-MYC is suppressed by Hhex. *Oncogene* (2015) 34:3011–22. doi:10.1038/onc.2014.240

112. Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, et al. Inhibitor of MYC identified in a Kröhnke pyridine library. *Proc Natl Acad Sci U S A* (2014) 111:12556–61. doi:10.1073/pnas.1319488111

113. Raffeiner P, Rock R, Schrafl A, Hartl M, Hart JR, Janda KD, et al. In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. *Oncotarget* (2014) 5:8869–78. doi:10.18632/oncotarget.2588

114. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. *Nat Rev Drug Discov* (2011) 10:351–64. doi:10.1038/nrd3374

115. Lin CJ, Nasr Z, Premsrirut PK, Porco JA Jr, Hippo Y, Lowe SW, et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis. *Cell Rep* (2012) 1:325–33. doi:10.1016/j.celrep.2012.02.010

116. Kang J, Sergio CM, Sutherland RL, Musgrove EA. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells. *BMC Cancer* (2014) 14:32. doi:10.1186/1471-2407-14-32

117. Zhou Z, Patel M, Ng N, Hsieh MH, Orth AP, Walker JR, et al. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening. *BMC Cancer* (2014) 14:944. doi:10.1186/1471-2407-14-944

**Conflict of Interest Statement:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Hartl. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.